The Citric Acid Cycle (Krebs Cycle)

◆Overall Stoichiometry

Discovered by Hans Krebs in 1937 (Nobel 1953), the TCA cycle operates exclusively in the mitochondrial matrix (eukaryotes) or cytoplasm (prokaryotes). Per turn:

The overall standard free energy change is \(\Delta G^{\circ\prime} \approx -40\;\text{kJ/mol}\)per turn, dominated by citrate synthase, isocitrate DH, and \(\alpha\)-KG DH. Since each glucose produces two pyruvate and each pyruvate one acetyl-CoA, the cycle runs twice per glucose.

◆The Eight Reactions

◆Simulation 1: ODE Model of the Krebs Cycle

Fourteen coupled ODEs capture each intermediate along with NAD⁺/NADH, FAD/FADH₂, and GDP/GTP pools. Product inhibition is implemented on citrate synthase (NADH, succinyl-CoA), IDH, and \(\alpha\)-KG DH. External sink terms emulate ETC regeneration of NAD⁺/FAD.

◆Regulation: Ca²⁺ and the NAD⁺/NADH Ratio

The cycle is controlled at three enzymes by a trio of physiological signals: NAD⁺/NADH ratio, ATP/ADP ratio, and matrix [Ca²⁺]. Crucially, calcium serves as the master activator: when a cell is stimulated to do work (muscle contraction, hormone signaling), cytosolic Ca²⁺ rises, some enters the matrix through the MCU (mitochondrial calcium uniporter), and simultaneously activates pyruvate DH, IDH, and \(\alpha\)-KG DH—pouring reduced cofactors into the ETC to match the increased ATP demand.

◆Anaplerotic Reactions

TCA intermediates are constantly siphoned off for biosynthesis (heme, amino acids, gluconeogenesis, lipogenesis). Anaplerotic (from Greek “to fill up”) reactions replenish the pool:

◆Pyruvate Dehydrogenase: The Gateway

Technically not a TCA enzyme, but functionally the gateway feeding it. Pyruvate dehydrogenase (PDH) is a giant multi-enzyme complex (~9 MDa in mammals) containing three catalytic subunits—E1 (decarboxylase, TPP-dependent), E2 (lipoamide acyltransferase), E3 (dihydrolipoyl DH, FAD/NAD-dependent)—plus two regulatory enzymes (PDH kinase, PDH phosphatase) bound to E2.

The swinging lipoyl arm of E2 visits each of the three active sites in turn, channeling substrates through covalent intermediates. PDH is inhibited by phosphorylation(PDK1-4 kinases activated by NADH, acetyl-CoA, ATP) and activated by dephosphorylation (PDP phosphatase activated by Ca²⁺, Mg²⁺, insulin). Dichloroacetate inhibits PDK, shifting flux from lactate to acetyl-CoA—investigated for lactic acidosis and cancer.

◆Thermodynamics: Standard vs Cellular \(\Delta G\)

The standard free energy changes computed at 1 M concentrations of reactants and products often look unfavorable (step 8 malate DH: \(+29.7\;\text{kJ/mol}\)) but inside cells the mass-action ratios are far from equilibrium. The cellular \(\Delta G = \Delta G^{\circ\prime} + RT\ln Q\) incorporates real concentrations and shows every reaction of the cycle proceeds spontaneously forward under physiological conditions. Three steps are notably far from equilibrium—citrate synthase (\(-53.9\)), IDH (\(-17.5\)), and \(\alpha\)-KG DH (\(-43.9\))—and these are the three regulated, rate-limiting enzymes. Near-equilibrium steps (aconitase, fumarase, MDH) are freely reversible and serve primarily as chemical relays.

◆Cellular Context: Compartmentalization and Transport

The TCA cycle operates in the mitochondrial matrix, but many of its intermediates serve dual roles in cytosolic pathways. The inner mitochondrial membrane is impermeable to most metabolites and specific transporters shuttle substrates in and out:

◆The TCA Cycle as a Biosynthetic Hub

Far from being merely a catabolic engine, the TCA cycle is a biosynthetic crossroads whose intermediates supply the building blocks of macromolecules:

• Citrate: exported to cytosol for fatty acid and cholesterol synthesis via ATP-citrate lyase
• \(\alpha\)-KG: precursor of glutamate, glutamine, proline, arginine; substrate for \(\alpha\)-KG-dependent dioxygenases (prolyl hydroxylases, TET2, JmjC)
• Succinyl-CoA: precursor of heme (via \(\delta\)-aminolevulinate synthase), porphyrins, and ketone body uptake by peripheral tissues (SCOT)
• Fumarate: byproduct of urea cycle and purine synthesis re-entry point
• OAA: transaminates to aspartate for pyrimidine synthesis, urea cycle, and gluconeogenesis

◆ODE Models of the Krebs Cycle

Quantitative modeling of the TCA cycle treats each metabolite concentration as a state variable evolving in time according to the difference of producing and consuming fluxes. The canonical state vector contains the eight cycle intermediates,

\[ \mathbf{x}(t) \;=\; \big(\,[\text{Cit}],\,[\text{IsoCit}],\,[\alpha\text{KG}],\,[\text{SucCoA}],\,[\text{Suc}],\,[\text{Fum}],\,[\text{Mal}],\,[\text{OAA}]\,\big), \]

augmented in real models by cofactor pools (NAD⁺/NADH, FAD/FADH₂, ATP/ADP, CoA, GTP/GDP, CO₂, Ca²⁺) shared with the ETC and cytosol. The general ODE system reads

\[ \frac{dx_i}{dt} \;=\; \sum_{j} S_{ij}\,v_j(\mathbf{x},\mathbf{p}), \]

where \(S\) is the stoichiometric matrix and the \(v_j\)are enzyme-kinetic rate laws parametrised by \(\mathbf{p}=(V_{\max,j}, K_{m,j},K_{i,j},\dots)\). The eight-step structure of Section above gives an \(8\times 8\) \(S\) (or wider when cofactors are tracked), with \(+1/-1\) entries on the cycle and additional rows for anaplerotic/cataplerotic exits at OAA and \(\alpha\)-KG.

Three modeling tiers

Enzyme rate-law choices, by step

Minimal 4-state worked example

Condensing to four lumped pools \(\{[\text{Cit}],[\alpha\text{KG}],[\text{Suc}],[\text{Mal}]\}\)with fixed cofactors gives a tractable system that already reproduces the qualitative NADH transient on a Ca²⁺ step:

\[ \begin{aligned} \dot{[\text{Cit}]} &= v_{CS}([\text{OAA}],[\text{AcCoA}]) - v_{IDH}([\text{Cit}],\text{NAD}^+),\\ \dot{[\alpha\text{KG}]} &= v_{IDH} - v_{KGDH}([\alpha\text{KG}],\text{NAD}^+,\text{Ca}^{2+}),\\ \dot{[\text{Suc}]} &= v_{KGDH} - v_{SDH}([\text{Suc}],\text{FAD}),\\ \dot{[\text{Mal}]} &= v_{SDH} - v_{MDH}([\text{Mal}],\text{NAD}^+), \end{aligned} \]

closed by a quasi-steady relation \([\text{OAA}] = v_{MDH}/k_{\text{out}}\) or by adding OAA as a fifth state. Each \(v_j\) is reversible Michaelis–Menten, e.g.

\[ v_{IDH} \;=\; V_{\max}^{IDH}\,\frac{[\text{Cit}]/K_m^{Cit} - [\alpha\text{KG}][\text{NADH}]/(K_m^{Cit}K_m^{NAD}\!\cdot\!K_{eq})}{(1+[\text{Cit}]/K_m^{Cit}+[\alpha\text{KG}]/K_m^{\alpha KG})(1+[\text{NAD}^+]/K_m^{NAD}+[\text{NADH}]/K_i^{NADH})}, \]

with allosteric Ca²⁺ activation modeled as \(V_{\max}\to V_{\max}\,(1+\alpha\,[\text{Ca}^{2+}]^h/(K_{0.5}^h+[\text{Ca}^{2+}]^h))\)(Hill exponent \(h\!\approx\!2\)). This single feature—the Hill activation by mitochondrial Ca²⁺—is what couples cytosolic Ca²⁺transients to NADH supply for the ETC, the central physiological insight of Cortassa–Aon (2003).

Landmark published models

What ODE Krebs models are used for

• Metabolic Control Analysis (MCA). Flux-control coefficients \(C^J_i = \frac{\partial \ln J}{\partial \ln v_i}\) satisfy the summation theorem \(\sum_i C^J_i = 1\). For TCA, the bulk of control sits at IDH and KGDH; CS and aconitase are typically near equilibrium.
• Demand response. ODE simulation predicts the dynamic NADH/NAD⁺ ratio in response to ADP load or Ca²⁺pulses, setting ETC supply.
• Coupling to ¹³C MFA. Positional carbon-isotopomer dynamics constrain branching at OAA (anaplerosis from pyruvate via PC vs. oxidative flux through CS), via labelling-augmented ODEs.
• Disease modeling. Fumarase/SDH deficiency, IDH1/2 neomorphic mutants, Leigh syndrome — ODE models predict metabolite accumulation patterns (succinate, fumarate, 2-hydroxyglutarate) consistent with clinical biomarkers.
• Drug-target prioritization. Sensitivity analysis of pathway flux to perturbations (e.g. metformin’s indirect Cx I effect propagating into TCA).